Merck: acquires Pandion Therapeutics
(CercleFinance.com) - Merck announced on Thursday that it has reached an agreement to acquire Pandion Therapeutics, a biotechnology company specializing in the treatment of autoimmune diseases, for 1.
85 billion dollars.
Under the terms of the deal, the US pharmaceutical giant plans to launch a friendly takeover bid of 60 dollars for each Pandion stock, which closed last night at a price of 25.6 dollars on the Nasdaq.
Merck explains that Pandion specializes in so-called "regulatory T" lymphocytes (Treg), immune cells that prevent each individual from triggering immune reactions against their own organs, which is an approach that is consistent with its strategy of multiplying therapeutic avenues.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
85 billion dollars.
Under the terms of the deal, the US pharmaceutical giant plans to launch a friendly takeover bid of 60 dollars for each Pandion stock, which closed last night at a price of 25.6 dollars on the Nasdaq.
Merck explains that Pandion specializes in so-called "regulatory T" lymphocytes (Treg), immune cells that prevent each individual from triggering immune reactions against their own organs, which is an approach that is consistent with its strategy of multiplying therapeutic avenues.
Copyright (c) 2021 CercleFinance.com. All rights reserved.